Yaoyigou released its 2026 interim report, with net profit attributable to the parent company at negative 9.5268 million yuan, a loss expansion of 278,400 yuan compared with the same period last year. The company's total operating revenue was 2.181 billion yuan, and net cash inflow from operating activities was 7.1471 million yuan. The latest asset-liability ratio was 59.30%, up 1.68 percentage points from the previous quarter and up 6.13 percentage points from the same period last year. The latest gross margin was 9.17%, down 0.98 percentage points from the previous quarter and down 1.65 percentage points from the same period last year. The latest ROE was negative 1.17%, down 0.26 percentage points from the same period last year. The company's diluted earnings per share was negative 0.10 yuan.
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd.Net loss widened year-on-year, with negative EPS and declining margins.
